Related Experiment Video
Updated: Feb 15, 2026
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Clinical Development of PD-1 in Advanced Melanoma
Abstract:
The development of new treatment options has dramatically improved the landscape for patients with advanced melanoma. Part of these advances emerged through the identification of the importance of factors that regulate the immune system, including proteins that negatively modulate T cell-mediated responses termed "immune checkpoints." Indeed, blockade of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint served as a proof of principle that the manipulation of these molecules could induce robust anticancer effects, yet limited to a small percentage of patients. Targeting a distinct checkpoint, the PD-1 yielded improved outcomes and reduced toxicity compared with CTLA-4 blockade and, in separate studies, chemotherapy. More recently, combined CTLA-4/PD-1 blockade was shown to result in higher response rates, while accompanied by increased toxicity. In this article, we review the clinical development of anti-PD-1 monotherapy and combinations that may expand the benefit of immunotherapy for patients with advanced melanoma.
Insights
Immune checkpoint inhibitors, like anti-PD-1 therapy, have advanced melanoma treatment. This review explores anti-PD-1 monotherapy and combinations to improve immunotherapy benefits for advanced melanoma patients.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced melanoma treatment has improved with new therapies targeting the immune system.
- Immune checkpoints, such as CTLA-4 and PD-1, regulate T cell responses against cancer.
- CTLA-4 blockade demonstrated anticancer effects but benefited few patients.
Purpose of the Study:
- To review the clinical development of anti-PD-1 monotherapy for advanced melanoma.
- To examine combination immunotherapies involving CTLA-4 and PD-1 blockade.
- To discuss expanding immunotherapy benefits for advanced melanoma patients.
Main Methods:
- Review of clinical trials and studies on immune checkpoint inhibitors.
- Analysis of anti-PD-1 monotherapy efficacy and safety.
- Evaluation of combination CTLA-4/PD-1 blockade outcomes and toxicities.
Main Results:
- PD-1 blockade shows improved outcomes and reduced toxicity compared to CTLA-4 blockade and chemotherapy.
- Combined CTLA-4/PD-1 blockade increases response rates but also toxicity.
- Anti-PD-1 monotherapy and combinations represent significant advances in melanoma immunotherapy.
Conclusions:
- Immune checkpoint blockade, particularly targeting PD-1, has transformed advanced melanoma treatment.
- Combination therapies are being explored to enhance response rates, balancing efficacy with toxicity.
- Further research aims to broaden the application and effectiveness of immunotherapy in melanoma.
Related Concept Videos
01:14Piaget's Stage 1 of Cognitive Development
Exploration...
01:26PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
01:07Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
01:24Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods